Clinical trial · Interventional
Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)
Forming a Comprehensive Treatment Plan for the Treatment of Hepatitis B Virus Related Hepatocellular Carcinoma With the Core Principles of Fuzheng Jiedu Huayu
NCT05152498CI-TRIAL-00055456unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fu Zheng Jie Du Hua Yu therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Fu Zheng Jie Du Hua Yu therapy
- interventionNames
- Drug: Fu Zheng Jie Du Hua Yu therapy
- type
- EXPERIMENTAL
- label
- Routine medical care
- interventionNames
- Drug: Fu Zheng Jie Du Hua Yu therapy
Primary outcomes (1)
- measure
- Time to Progression
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Meet the criteria of hepatocellular carcinoma * Ages Eligible for Study: ≤75 years old; * Informed consent from the patient. Exclusion Criteria: * Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug
References
Publications (0)
Data not yet available
No reference posted for this study.